Clinerion has expanded its geographic coverage to include over 60 million patients in the U.S., via a strategic partnership with Provisio. Clinerion now has a truly global footprint for its services for clinical trial patient search and identification, and data generation for real-world evidence and market access activities.

Clinerion leverages the electronic health records of patients at its network of partner hospitals, hospital clusters and hospital information system providers to provide patient data analytics services supporting clinical research, development and marketing. In the past twelve months, Clinerion’s coverage has expanded across Europe, Asia and South America. With Provisio’s 60 million patients in the U.S., this new partnership extends Clinerion’s coverage in the Americas.

Clinerion’s technology allows the search for eligible candidate patients in its partner hospitals for participation in clinical trials in real-time and the re-identification of these patients from their anonymized records by authorized clinical trial staff. Anonymized patient data at partner hospitals may also be queried to provide data for real-world evidence studies and market access initiatives.

This partnership also brings Provisio’s Outreach Assistance service into Clinerion’s portfolio of patient recruitment capabilities for the U.S. This service supports traditional outreach and enrollment efforts by providing data-driven intelligence on where pre-qualified patients are. Clients can optimize existing media and outreach programs by focusing on areas with high concentrations of pre-qualified patients and avoiding areas with few of them.

With this partnership, hospitals, hospital clusters and trials sites in the U.S. will gain exposure to the international clinical trials run by Clinerion’s clients. Trial managers for both academic and sponsored trials will benefit from a more efficient, single-point-of-access to patients on a global scale.

“Provisio is pleased to gain access to Clinerion’s broad data footprint outside the United States,” said Mike Hassell, CEO of Provisio.

“We are thrilled to have Provisio as our partner in the USA,” said Ulf Claesson, CEO of Clinerion. “Not only do they provide us with the means to expand our service offering to the important U.S. market, but they will become a key local resource in the U.S. for Clinerion. This is the next step for Clinerion in the Americas.”

Clinerion’s hospital, clinic and medical practice coverage currently comprises almost 80 million patient lives, spanning three continents. Clinerion is continuing to pursue expansion of its network across additional countries.